SALT Study (Switching to the Administration of Lithium Slow -Release Treatment)

Condition:   Bipolar Disorder Interventions:   Drug: Lithium sulphate prolonged-release 660 mg;   Drug: Lithium carbonate immediate-release 150 mg and 300 mg Sponsors:   Aziende Chimiche Riunite Angelini Francesco S.p.A;   Mediolanum Cardio Research Recruiting - verified June 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials